Adenovirus and Immunotherapy: Advancing Cancer Treatment by Combination

Sato-Dahlman, Mizuho; LaRocca, Christopher J.; Yanagiba, Chikako; Yamamoto, Masato

doi:10.3390/cancers12051295

Cited by 36 publications

(28 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunological interventions with checkpoint inhibitors, antibodies, vaccination programmes and cell therapies show ample promise [36][37][38][39][40]. In addition, developments in radiobiology and radiophysics have boosted innovation in radiation therapies; for example, novel fractionated radiation regimens, use of different sources (photons, protons and light ions), or combination with other treatments offer new perspectives [41][42][43][44][45].…”

Section: Development Of New Therapiesmentioning

confidence: 99%

Towards a cancer mission in Horizon Europe: recommendations

et al. 2020

View full text Add to dashboard Cite

A comprehensive translational cancer research approach focused on personalized and precision medicine, and covering the entire cancer researchcare-prevention continuum has the potential to achieve in 2030 a 10-year cancer-specific survival for 75% of patients diagnosed in European Union (EU) member states with a well-developed healthcare system. Concerted actions across this continuum that spans from basic and preclinical research through clinical and prevention research to outcomes research, along with the establishment of interconnected high-quality infrastructures for translational research, clinical and prevention trials and outcomes research, will ensure that science-driven and social innovations benefit patients and individuals at risk across the EU. European infrastructures involving comprehensive cancer centres (CCCs) and CCC-like entities will provide researchers with access to the required critical mass of patients, biological materials and technological resources and can bridge research with healthcare systems. Here, we prioritize research areas to ensure a balanced research portfolio and provide recommendations for achieving key targets. Meeting these targets will require harmonization of EU and national priorities and policies, improved research coordination at the national, regional and EU level and increasingly efficient and flexible funding mechanisms. Long-term support by the EU and commitment of Member States to specialized schemes are also needed for the establishment and sustainability of trans-border infrastructures and networks. In addition to effectively engaging policymakers, all relevant stakeholders within the entire continuum should consensually inform policy through evidencebased advice.

show abstract

Section: Development Of New Therapiesmentioning

confidence: 99%

Towards a cancer mission in Horizon Europe: recommendations

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Otherwise, the effectiveness in the use of neoantigens has already been observed in preclinical [ 198 , 199 ] and clinical data [ 200 , 201 , 202 ]. In addition, patients with high mutation burden tumors, like melanoma [ 203 , 204 ], non small-cell lung cancer [ 205 ], and bladder cancer [ 206 ], have had more clinical benefit from checkpoint-blockade therapy than those with lower mutation loads [ 196 ].…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Nonreplicating Adenoviral Vectors: Improving Tropism and Delivery of Cancer Gene Therapy

Tessarollo

Domingues

Antunes

et al. 2021

Cancers

View full text Add to dashboard Cite

Recent preclinical and clinical studies have used viral vectors in gene therapy research, especially nonreplicating adenovirus encoding strategic therapeutic genes for cancer treatment. Adenoviruses were the first DNA viruses to go into therapeutic development, mainly due to well-known biological features: stability in vivo, ease of manufacture, and efficient gene delivery to dividing and nondividing cells. However, there are some limitations for gene therapy using adenoviral vectors, such as nonspecific transduction of normal cells and liver sequestration and neutralization by antibodies, especially when administered systemically. On the other hand, adenoviral vectors are amenable to strategies for the modification of their biological structures, including genetic manipulation of viral proteins, pseudotyping, and conjugation with polymers or biological membranes. Such modifications provide greater specificity to the target cell and better safety in systemic administration; thus, a reduction of antiviral host responses would favor the use of adenoviral vectors in cancer immunotherapy. In this review, we describe the structural and molecular features of nonreplicating adenoviral vectors, the current limitations to their use, and strategies to modify adenoviral tropism, highlighting the approaches that may allow for the systemic administration of gene therapy.

show abstract

“…A large variety of oncolytic viral families have been investigated in various preclinical and clinical cancer studies [23]. These cover both single-stranded and double-stranded RNA and DNA viruses, including measles virus, vesicular stomatitis virus (VSV), reovirus, type 1 herpes simplex s (HSV-1), Newcastle disease virus (NDV), adenovirus, and poxviruses (vaccinia and myxoma viruses) [24][25][26][27][28][29][30][31][32][33]. As reviewed by Yang and colleagues, multiple viral and tumoral factors can impact OV therapy [24], but there are no general rules to predict the oncolytic efficiency of any OV with any target cancer, in part because the tumor microenvironment can vary widely, even within a single cancer patient.…”

Section: Oncolytic Viral Therapymentioning

confidence: 99%

Simultaneous Tumor and Stroma Targeting by Oncolytic Viruses

et al. 2020

View full text Add to dashboard Cite

Current cancer therapeutics often insufficiently eradicate malignant cells due to the surrounding dense tumor stroma. This multi-componential tissue consists of mainly cancer-associated fibroblasts, the (compact) extracellular matrix, tumor vasculature, and tumor-associated macrophages, which all exert crucial roles in maintaining a pro-tumoral niche. Their continuous complex interactions with tumor cells promote tumor progression and metastasis, emphasizing the challenges in tumor therapy development. Over the last decade, advances in oncolytic virotherapy have shown that oncolytic viruses (OVs) are a promising multi-faceted therapeutic platform for simultaneous tumor and stroma targeting. In addition to promoting tumor cell oncolysis and systemic anti-tumor immunity, accumulating data suggest that OVs can also directly target stromal components, facilitating OV replication and spread, as well as promoting anti-tumor activity. This review provides a comprehensive overview of the interactions between native and genetically modified OVs and the different targetable tumor stromal components, and outlines strategies to improve stroma targeting by OVs.

show abstract

Adenovirus and Immunotherapy: Advancing Cancer Treatment by Combination

Cited by 36 publications

References 103 publications

Towards a cancer mission in Horizon Europe: recommendations

Towards a cancer mission in Horizon Europe: recommendations

Nonreplicating Adenoviral Vectors: Improving Tropism and Delivery of Cancer Gene Therapy

Simultaneous Tumor and Stroma Targeting by Oncolytic Viruses

Contact Info

Product

Resources

About